Element Genomics is a discovery stage biotechnology company, focused on finding breakthrough cures for severe human disease through the use of functional genomics and manipulation of the epigenome. With close ties to Duke, the firm is developing a high-throughput platform for understanding gene regulatory elements in order to identify new drug targets for common diseases. At the core of the Element Genomics platform is a suite of technologies to improve understanding of genome structure and function such as CRISPR editing technologies used for genomic and epigenomic regulatory region analysis and modulation, underpinned and enabled with advanced informatics capabilities, and driven by a strong scientific team. In April 2018 it was announced that the firm had been acquired for $30M by biopharmaceutical and specialty chemical company UCB Pharma.
